EGFR and lung adenocarcinoma: For further in vivo evidence, and given the important roles of EGFR/MAPK/ERK/CREB in lung adenocarcinoma, we evaluated the Cancer Genome Atlas (TCGA) lung adenocarcinoma RNA-seq results, comparing MAPK/ERK activating KRASG12X mutant (X is A, C, D, S, or V) with non-variant samples.